Last reviewed · How we verify
NCT06301191
The Effect of Semaglutide on Cardiovascular Markers and Liver Function
trial testing Semaglutide, 1.0 mg/mL in Diabetes Type 2 in 50 participants. Status unknown.
1 March 2023
Quick facts
| Lead sponsor | Attikon Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 March 2022 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Semaglutide, 1.0 mg/mL — full drug profile →
- Dipeptidyl Peptidase 4 inhibitor — full drug profile →
Conditions studied
- Diabetes Type 2 — all drugs for Diabetes Type 2 →
Sponsor
Attikon Hospital
Who can join
Adults 18 to 80, any sex, with Diabetes Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.
Korakas E, Kountouri A, Pavlidis G, Oikonomou E, et al · · 2024 · cited 10× · PMID 38979402 · DOI 10.1210/jendso/bvae122 -
Response to "Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'".
Korakas E, Kountouri A, Pavlidis G, Oikonomou E, et al · · 2024 · PMID 39711847 · DOI 10.1210/jendso/bvae218
Verify or expand the search:
- PubMed search for NCT06301191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Semaglutide, 1.0 mg/mL
Trials testing the same drug.
- NCT05670379 — Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant · Phase 1 · completed
- NCT05938712 — The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist · Phase 2 · recruiting
- NCT03598621 — A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools · Phase 1 · completed
Other recruiting trials for Diabetes Type 2
Currently open trials in the same condition.
- NCT07176793 — Pregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes · recruiting
- NCT07485075 — Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical · NA · recruiting
- NCT07220213 — FELLAShip to Better Health · NA · recruiting
- NCT07350967 — Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel End · NA · recruiting
- NCT07149610 — Connected Care for Type 2 Diabetes Self-Management · NA · recruiting
Other Attikon Hospital trials
Trials by the same sponsor.
- NCT07425457 — Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial) · NA · recruiting
- NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
- NCT06810700 — The Association Between Time in Range With Markers of Endothelial and Cardiovascular Function · not yet recruiting
- NCT06978387 — The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes. · active not recruiting
- NCT06749613 — Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06301191 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Attikon Hospital
- Last refreshed: 8 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06301191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing